Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cancer-specific uptake of a liganded protein nanocarrier targeting aggressive CXCR4⁺ colorectal cancer models

  • Céspedes, María Virtudes|||0000-0003-2956-5833
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Álamo, Patricia|||0000-0003-0510-5701
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Sala Faig, Rita
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Pavón Ribas, Miguel Ángel
  • Mangues, Ma Antonia|||0000-0002-1438-8515
  • Trias Folch, Manuel
  • López Pousa, Antonio|||0000-0003-1066-3951
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • Mangues, Ramon|||0000-0003-2661-9525
Unliganded drug-nanoconjugates accumulate passively in the tumor whereas liganded nanoconjugates promote drug internalization in tumor cells via endocytosis and increase antitumor efficacy. Whether or not tumor cell internalization associates with enhanced tumor uptake is still under debate. We here compared tumor uptake of T22-GFP-H6, a liganded protein carrier targeting the CXCR4 receptor, and the unliganded GFP-H6 carrier in subcutaneous and metastatic colorectal cancer models. T22-GFP-H6 had a higher tumor uptake in primary tumor and metastatic foci than GFP-H6, with no biodistribution or toxicity on normal tissues. T22-GFP-H6 was detected in target CXCR4+ tumor cell cytosol whereas GFP-H6 was detected in tumor stroma. SDF1-α co-administration switched T22-GFP-H6 internalization from CXCR4+ tumor epithelial cells to the stroma. Therefore, the incorporation of a targeting ligand promotes selective accumulation of the nanocarrier inside target tumor cells while increasing whole tumor uptake in a CXCR4-dependent manner, validating T22-GFP-H6 as a CXCR4-targeted drug carrier.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Recombinant pharmaceuticals from microbial cells, a 2015 update

  • Sánchez-García, Laura|||0000-0002-8420-1701
  • Martín, Lucas
  • Mangues, Ramon|||0000-0003-2661-9525
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Vázquez, Esther|||0000-0003-1052-0424
  • Villaverde, Antonio|||0000-0002-2615-4521
Diabetes, growth or clotting disorders are among the spectrum of human diseases related to protein absence or malfunction. Since these pathologies cannot be yet regularly treated by gene therapy, the administration of functional proteins produced ex vivo is required. As both protein extraction from natural producers and chemical synthesis undergo inherent constraints that limit regular large-scale production, recombinant DNA technologies have rapidly become a choice for therapeutic protein production. The spectrum of organisms exploited as recombinant cell factories has expanded from the early predominating Escherichia coli to alternative bacteria, yeasts, insect cells and especially mammalian cells, which benefit from metabolic and protein processing pathways similar to those in human cells. Up to date, around 650 protein drugs have been worldwide approved, among which about 400 are obtained by recombinant technologies. Other 1300 recombinant pharmaceuticals are under development, with a clear tendency towards engineered versions with improved performance and new functionalities regarding the conventional, plain protein species. This trend is exemplified by the examination of the contemporary protein-based drugs developed for cancer treatment.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Selective depletion of metastatic stem cells as therapy for human colorectal cancer

  • Céspedes, María Virtudes|||0000-0003-2956-5833
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Aviñó, Ana|||0000-0003-3047-738X
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Álamo, Patricia|||0000-0003-0510-5701
  • Sala, Rita
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Mangues, Ma Antonia|||0000-0002-1438-8515
  • López Pousa, Antonio|||0000-0003-1066-3951
  • Eritja, Ramon|||0000-0001-5383-9334
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • Mangues, Ramon|||0000-0003-2661-9525
Selective elimination of metastatic stem cells (MetSCs) promises to block metastatic dissemination. Colorectal cancer (CRC) cells overexpressing CXCR4 display trafficking functions and metastasis-initiating capacity. We assessed the antimetastatic activity of a nanoconjugate (T22-GFP-H6-FdU) that selectively delivers Floxuridine to CXCR4 cells. In contrast to free oligo-FdU, intravenous T22-GFP-H6-FdU selectively accumulates and internalizes in CXCR4 cancer cells, triggering DNA damage and apoptosis, which leads to their selective elimination and to reduced tumor re-initiation capacity. Repeated T22-GFP-H6-FdU administration in cell line and patient-derived CRC models blocks intravasation and completely prevents metastases development in 38-83% of mice, while showing CXCR4 expression-dependent and site-dependent reduction in foci number and size in liver, peritoneal, or lung metastases in the rest of mice, compared to free oligo-FdU. T22-GFP-H6-FdU induces also higher regression of established metastases than free oligo-FdU, with negligible distribution or toxicity in normal tissues. This targeted drug delivery approach yields potent antimetastatic effect, through selective depletion of metastatic CXCR4 cancer cells, and validates metastatic stem cells (MetSCs) as targets for clinical therapy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Intrinsic functional and architectonic heterogeneity of tumor-targeted protein nanoparticles

  • Pesarrodona Roches, Mireia|||0000-0001-9669-8471
  • Crosas, Eva|||0000-0002-2408-0071
  • Cubarsi, Rafael
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • Saccardo, Paolo|||0000-0002-3092-1404
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Rueda, Fabian
  • Sánchez-García, Laura|||0000-0002-8420-1701
  • Serna, Naroa|||0000-0001-5682-8198
  • Mangues, Ramon|||0000-0003-2661-9525
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Vázquez, Esther|||0000-0003-1052-0424
  • Villaverde, Antonio|||0000-0002-2615-4521
Self-assembling proteins are gaining attention as building blocks for application-tailored nanoscale materials. This is mostly due to the biocompatibility, biodegradability, and functional versatility of peptide chains. Such a potential for adaptability is particularly high in the case of recombinant proteins, which are produced in living cells and are suitable for genetic engineering. However, how the cell factory itself and the particular protein folding machinery influence the architecture and function of the final material is still poorly explored. In this study we have used diverse analytical approaches, including small-angle X-ray scattering (SAXS) and field emission scanning electron microscopy (FESEM) to determine the fine architecture and geometry of recombinant, tumor-targeted protein nanoparticles of interest as drug carriers, constructed on a GFP-based modular scheme. A set of related oligomers were produced in alternative Escherichia coli strains with variant protein folding networks. This resulted in highly regular populations of morphometric types, ranging from 2.4 to 28 nm and from spherical- to rod-shaped materials. These differential geometric species, whose relative proportions were determined by the features of the producing strain, were found associated with particular fluorescence emission, cell penetrability and receptor specificity profiles. Then, nanoparticles with optimal properties could be analytically identified and further isolated from producing cells for use. The cell's protein folding machinery greatly modulates the final geometry reached by the constructs, which in turn defines the key parameters and biological performance of the material.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Release of targeted protein nanoparticles from functional bacterial amyloids, A death star-like approach

  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Céspedes, María Virtudes|||0000-0003-2956-5833
  • Sala, Rita
  • Álamo, Patricia|||0000-0003-0510-5701
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • Pesarrodona Roches, Mireia|||0000-0001-9669-8471
  • Sánchez-García, Laura|||0000-0002-8420-1701
  • Cano-Garrido, Olivia|||0000-0002-5504-2131
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • Mangues, Ramon|||0000-0003-2661-9525
  • Seras-Franzoso, Joaquin|||0000-0002-7893-4773
Sustained release of drug delivery systems (DDS) has the capacity to increase cancer treatment efficiency in terms of drug dosage reduction and subsequent decrease of deleterious side effects. In this regard, many biomaterials are being investigated but none offers morphometric and functional plasticity and versatility comparable to protein-based nanoparticles (pNPs). Here we describe a new DDS by which pNPs are fabricated as bacterial inclusion bodies (IB), that can be easily isolated, subcutaneously injected and used as reservoirs for the sustained release of targeted pNPs. Our approach combines the high performance of pNP, regarding specific cell targeting and biodistribution with the IB supramolecular organization, stability and cost effectiveness. This renders a platform able to provide a sustained source of CXCR4-targeted pNPs that selectively accumulate in tumor cells in a CXCR4 colorectal cancer xenograft model. In addition, the proposed system could be potentially adapted to any other protein construct offering a plethora of possible new therapeutic applications in nanomedicine.